S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Trustees picked by DeSantis may change progressive college
The Next Big Crisis Is Here (Ad)
Qatar replaces Russian company in Lebanon gas exploration
France must raise pension age to 64, prime minister says
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Trustees picked by DeSantis may change progressive college
The Next Big Crisis Is Here (Ad)
Qatar replaces Russian company in Lebanon gas exploration
France must raise pension age to 64, prime minister says
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Trustees picked by DeSantis may change progressive college
The Next Big Crisis Is Here (Ad)
Qatar replaces Russian company in Lebanon gas exploration
France must raise pension age to 64, prime minister says
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Trustees picked by DeSantis may change progressive college
The Next Big Crisis Is Here (Ad)
Qatar replaces Russian company in Lebanon gas exploration
France must raise pension age to 64, prime minister says
NASDAQ:SUPN

Supernus Pharmaceuticals - SUPN Stock Forecast, Price & News

$40.68
-0.38 (-0.93%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$40.56
$41.20
50-Day Range
$34.63
$41.41
52-Week Range
$24.95
$41.69
Volume
354,410 shs
Average Volume
335,813 shs
Market Capitalization
$2.20 billion
P/E Ratio
63.56
Dividend Yield
N/A
Price Target
$47.00

Supernus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
15.5% Upside
$47.00 Price Target
Short Interest
Bearish
10.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.35
Upright™ Environmental Score
News Sentiment
0.99mentions of Supernus Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$2.63 M Sold Last Quarter
Proj. Earnings Growth
-58.90%
From $1.63 to $0.67 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

728th out of 1,054 stocks

Pharmaceutical Preparations Industry

365th out of 517 stocks


SUPN stock logo

About Supernus Pharmaceuticals (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Receive SUPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SUPN Stock News Headlines

The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
SUPN Supernus Pharmaceuticals, Inc.
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Supernus Pharma's Charts Are Looking Super
Supernus Announces Third Quarter 2022 Financial Results
Axsome Therapeutics: All Eyes On Auvelity Launch
Supernus Provides Regulatory Update on SPN-830
Supernus Pharmaceuticals (NASDAQ: SUPN)
Best Momentum Stocks to Buy for August 8th
See More Headlines
Receive SUPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SUPN Company Calendar

Last Earnings
11/08/2022
Today
1/29/2023
Next Earnings (Estimated)
4/12/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:SUPN
CUSIP
86845910
Employees
575
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$47.00
High Stock Price Forecast
$47.00
Low Stock Price Forecast
$47.00
Forecasted Upside/Downside
+15.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$53.42 million
Pretax Margin
4.20%

Debt

Sales & Book Value

Annual Sales
$579.78 million
Cash Flow
$1.97 per share
Book Value
$15.43 per share

Miscellaneous

Free Float
49,739,000
Market Cap
$2.20 billion
Optionable
Optionable
Beta
0.94

Key Executives

  • Jack A. Khattar
    President, CEO, Secretary & Director
  • Timothy C. Dec
    Chief Financial Officer & Senior Vice President
  • Frank Mottola
    Senior VP-Quality, GMP Operations & IT
  • Padmanabh P. Bhatt
    Chief Scientific Officer & Senior Vice President
  • Jonathan Rubin
    Chief Medical Officer & Senior Vice President













SUPN Stock - Frequently Asked Questions

Should I buy or sell Supernus Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SUPN shares.
View SUPN analyst ratings
or view top-rated stocks.

What is Supernus Pharmaceuticals' stock price forecast for 2023?

1 Wall Street research analysts have issued 12-month price objectives for Supernus Pharmaceuticals' stock. Their SUPN share price forecasts range from $47.00 to $47.00. On average, they expect the company's stock price to reach $47.00 in the next year. This suggests a possible upside of 15.5% from the stock's current price.
View analysts price targets for SUPN
or view top-rated stocks among Wall Street analysts.

How have SUPN shares performed in 2023?

Supernus Pharmaceuticals' stock was trading at $35.67 at the start of the year. Since then, SUPN shares have increased by 14.0% and is now trading at $40.68.
View the best growth stocks for 2023 here
.

When is Supernus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 12th 2023.
View our SUPN earnings forecast
.

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) issued its quarterly earnings results on Tuesday, November, 8th. The specialty pharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.32 by $0.29. The specialty pharmaceutical company had revenue of $177.35 million for the quarter, compared to analysts' expectations of $173.22 million. Supernus Pharmaceuticals had a trailing twelve-month return on equity of 4.51% and a net margin of 5.72%.

What guidance has Supernus Pharmaceuticals issued on next quarter's earnings?

Supernus Pharmaceuticals issued an update on its FY 2022 earnings guidance on Thursday, December, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $650.00 million-$680.00 million, compared to the consensus revenue estimate of $674.36 million.

What is Jack A. Khattar's approval rating as Supernus Pharmaceuticals' CEO?

20 employees have rated Supernus Pharmaceuticals Chief Executive Officer Jack A. Khattar on Glassdoor.com. Jack A. Khattar has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Supernus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), GW Pharmaceuticals (GWPH), Netflix (NFLX), Corcept Therapeutics (CORT) and Cara Therapeutics (CARA).

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

Who are Supernus Pharmaceuticals' major shareholders?

Supernus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Stephens Investment Management Group LLC (2.97%), Rice Hall James & Associates LLC (1.15%), Congress Asset Management Co. MA (0.94%), Tributary Capital Management LLC (0.63%), Scout Investments Inc. (0.57%) and Phocas Financial Corp. (0.32%). Insiders that own company stock include Frederick M Hudson, Gregory S Patrick, Jack A Khattar, Padmanabh P Bhatt, Stefan KF Schwabe and Tami Tillotson Martin.
View institutional ownership trends
.

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Supernus Pharmaceuticals' stock price today?

One share of SUPN stock can currently be purchased for approximately $40.68.

How much money does Supernus Pharmaceuticals make?

Supernus Pharmaceuticals (NASDAQ:SUPN) has a market capitalization of $2.20 billion and generates $579.78 million in revenue each year. The specialty pharmaceutical company earns $53.42 million in net income (profit) each year or $0.64 on an earnings per share basis.

How many employees does Supernus Pharmaceuticals have?

The company employs 575 workers across the globe.

How can I contact Supernus Pharmaceuticals?

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The official website for the company is www.supernus.com. The specialty pharmaceutical company can be reached via phone at (301) 838-2500, via email at gpatrick@supernus.com, or via fax at 301-838-2501.

This page (NASDAQ:SUPN) was last updated on 1/29/2023 by MarketBeat.com Staff